259 related articles for article (PubMed ID: 28656526)
1. Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?
Rotondo Dottore G; Ionni I; Menconi F; Casini G; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Feb; 41(2):193-201. PubMed ID: 28656526
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).
Rotondo Dottore G; Ionni I; Menconi F; Casini G; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Jul; 41(7):815-820. PubMed ID: 29256181
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy.
Rotondo Dottore G; Leo M; Casini G; Latrofa F; Cestari L; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
Thyroid; 2017 Feb; 27(2):271-278. PubMed ID: 27824294
[TBL] [Abstract][Full Text] [Related]
4. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress.
Tsai CC; Wu SB; Kao SC; Kau HC; Lee FL; Wei YH
Mol Vis; 2013; 19():927-34. PubMed ID: 23687429
[TBL] [Abstract][Full Text] [Related]
6. Polydatin attenuates orbital oxidative stress in Graves' orbitopathy through the NRF2 pathway.
Li H; Min J; Chen Y; Li H; Zhang Y
Chem Biol Interact; 2020 Jan; 315():108894. PubMed ID: 31705858
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effect of Resveratrol on Oxidative Stress in Graves' Orbitopathy Orbital Fibroblasts.
Kim CY; Lee HJ; Chae MK; Byun JW; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6352-61. PubMed ID: 26436888
[TBL] [Abstract][Full Text] [Related]
8. Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts.
Botta R; Lisi S; Marcocci C; Sellari-Franceschini S; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Sisti E; Casini G; Nardi M; Pinchera A; Vitti P; Marinò M
Thyroid; 2013 Jan; 23(1):92-6. PubMed ID: 23030053
[TBL] [Abstract][Full Text] [Related]
9. Increased response to oxidative stress challenge in Graves' ophthalmopathy orbital fibroblasts.
Tsai CC; Wu SB; Cheng CY; Kao SC; Kau HC; Lee SM; Wei YH
Mol Vis; 2011; 17():2782-8. PubMed ID: 22065933
[TBL] [Abstract][Full Text] [Related]
10. Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy.
Ko J; Kim JY; Kim JW; Yoon JS
Endocr J; 2020 Apr; 67(4):439-447. PubMed ID: 31941844
[TBL] [Abstract][Full Text] [Related]
11. Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.
Guo Y; Li H; Chen X; Yang H; Guan H; He X; Chen Y; Pokharel S; Xiao H; Li Y
J Clin Endocrinol Metab; 2020 Jun; 105(6):1906-17. PubMed ID: 32249902
[TBL] [Abstract][Full Text] [Related]
12. Alteration of Connective Tissue Growth Factor (CTGF) Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Tsai CC; Wu SB; Chang PC; Wei YH
PLoS One; 2015; 10(11):e0143514. PubMed ID: 26599235
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effect of Protocatechuic Aldehyde in an In Vitro Model of Graves' Orbitopathy.
Byun JW; Hwang S; Kang CW; Kim JH; Chae MK; Yoon JS; Lee EJ
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4055-62. PubMed ID: 27494347
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy.
Kim BR; Kim J; Lee JE; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):39. PubMed ID: 32196098
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant Therapy in Graves' Orbitopathy.
Lanzolla G; Marcocci C; Marinò M
Front Endocrinol (Lausanne); 2020; 11():608733. PubMed ID: 33381085
[TBL] [Abstract][Full Text] [Related]
17. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
18. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid.
Lisi S; Botta R; Lemmi M; Sellari-Franceschini S; Altea MA; Sisti E; Casini G; Nardi M; Marcocci C; Pinchera A; Marinò M
J Endocrinol Invest; 2011; 34(7):521-7. PubMed ID: 21042042
[TBL] [Abstract][Full Text] [Related]
19. 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves' orbitopathy.
Yoon Y; Chae MK; Lee EJ; Yoon JS
Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1095-1102. PubMed ID: 31900640
[TBL] [Abstract][Full Text] [Related]
20. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
